Bottom line
GGHCX vs JEHSX: the short answer
GGHCX (INVESCO Health Care Fund) and JEHSX (Health Sciences Trust) share a meaningful slice of their top holdings — about 59% by weight.
But JEHSX is far broader, holding 173 positions to 82 for GGHCX, so beyond the top names it adds exposure GGHCX doesn't have.
JEHSX is cheaper at 1.04% vs 1.07% — a difference of $3.00 a year per $10,000 invested.
Over five years, JEHSX returned +4.2% a year vs +2.6% for GGHCX.
GGHCX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
GGHCX vs JEHSX side by side
| GGHCX | JEHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Invesco | John Hancock |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.07% | 1.04% |
| Annual cost per $10k | $107 | $104 |
| 10-yr cost on $10k (prospectus) | $1,784 | $1,282 |
| Max front load | 5.5% | — |
| 12b-1 fee | 0.25% | 0.05% |
| 1-yr return | +9.2% | +19.5% |
| 5-yr return (annualized) | +2.6% | +4.2% |
| 10-yr return (annualized) | +5.8% | +8.7% |
| Best quarter | +19.6% | +23.6% |
| Worst quarter | −16.5% | −16.1% |
| Net assets (fund) | $1.2B | $251.3M |
| Number of holdings | 82 | 173 |
| Portfolio turnover | 59% | 68% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | GGHCX | JEHSX | Difference |
|---|---|---|---|
| 2025 | +15.5% | +19.5% | −4.0% |
| 2024 | +4.0% | +1.8% | +2.2% |
| 2023 | +3.1% | +4.3% | −1.2% |
| 2022 | −13.5% | −13.1% | −0.4% |
| 2021 | +12.2% | +11.2% | +1.0% |
| 2020 | +14.5% | +27.2% | −12.7% |
| 2019 | +32.0% | +28.7% | +3.3% |
| 2018 | +0.5% | +0.7% | −0.2% |
| 2017 | +15.5% | +27.5% | −12.1% |
| 2016 | −11.7% | −10.6% | −1.1% |
Source: Fund prospectus bar charts
Holdings overlap
12 of GGHCX's top 25 holdings also appear in JEHSX's top 25.
| Holding | GGHCX | JEHSX |
|---|---|---|
| Eli Lilly and Co. | 10.59% | 14.30% |
| Johnson & Johnson | 6.76% | 6.33% |
| UnitedHealth Group Inc. | 6.17% | 5.95% |
| Merck & Co., Inc. | 4.59% | 4.21% |
| AbbVie Inc. | 4.03% | 5.28% |
| Gilead Sciences, Inc. | 3.63% | 2.95% |
| CVS Health Corp. | 2.52% | 0.98% |
| BrightSpring Health Services, Inc. | 2.20% | 0.88% |
| Cardinal Health, Inc. | 2.10% | 1.09% |
| Guardant Health, Inc. | 2.04% | 1.28% |
| Vertex Pharmaceuticals Inc. | 2.01% | 2.38% |
| Thermo Fisher Scientific Inc. | 1.55% | 2.67% |
Source: SEC Form N-PORT
GGHCX top 10
- Eli Lilly and Co. — 10.59%
- Johnson & Johnson — 6.76%
- UnitedHealth Group Inc. — 6.17%
- Invesco Private Prime Fund — 4.67%
- Merck & Co., Inc. — 4.59%
- AbbVie Inc. — 4.03%
- Gilead Sciences, Inc. — 3.63%
- argenx SE — 3.24%
- CVS Health Corp. — 2.52%
- Welltower Inc. — 2.34%
JEHSX top 10
- Eli Lilly and Company — 14.30%
- Johnson and Johnson — 6.33%
- UnitedHealth Group Incorporated — 5.95%
- AbbVie Inc. — 5.28%
- Merck and Co. Inc. — 4.21%
- Gilead Sciences Inc. — 2.95%
- Thermo Fisher Scientific Inc. — 2.67%
- Vertex Pharmaceuticals Incorporated — 2.38%
- Bristol-Myers Squibb Company — 2.22%
- Abbott Laboratories — 2.00%
FAQ
What is the difference between GGHCX and JEHSX?
Which is cheaper, GGHCX or JEHSX?
Should I own both GGHCX and JEHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.